Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Opioid prescribing for chronic musculoskeletal pain in UK primary care: results from a cohort analysis of the COPERS trial.

Ashaye T, Hounsome N, Carnes D, Taylor SJC, Homer K, Eldridge S, Spencer A, Rahman A, Foell J, Underwood MR; COPERS Study Team (ISRCTN 24426731).

BMJ Open. 2018 Jun 6;8(6):e019491. doi: 10.1136/bmjopen-2017-019491.

2.

Improving the self-management of chronic pain: COping with persistent Pain, Effectiveness Research in Self-management (COPERS).

Taylor SJC, Carnes D, Homer K, Pincus T, Kahan BC, Hounsome N, Eldridge S, Spencer A, Diaz-Ordaz K, Rahman A, Mars TS, Foell J, Griffiths CJ, Underwood MR.

Southampton (UK): NIHR Journals Library; 2016 Sep.

3.

Sleep in patients with primary dystonia: A systematic review on the state of research and perspectives.

Hertenstein E, Tang NK, Bernstein CJ, Nissen C, Underwood MR, Sandhu HK.

Sleep Med Rev. 2016 Apr;26:95-107. doi: 10.1016/j.smrv.2015.04.004. Epub 2015 May 9. Review.

PMID:
26164369
4.

Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.

Seki T, Suyama-Kagitani A, Kawauchi-Miki S, Miki S, Wakasa-Morimoto C, Akihisa E, Nakahara K, Kobayashi M, Underwood MR, Sato A, Fujiwara T, Yoshinaga T.

Antimicrob Agents Chemother. 2015 May;59(5):2596-606. doi: 10.1128/AAC.04844-14. Epub 2015 Feb 17.

5.

Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection.

Yoshinaga T, Kobayashi M, Seki T, Miki S, Wakasa-Morimoto C, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T.

Antimicrob Agents Chemother. 2015 Jan;59(1):397-406. doi: 10.1128/AAC.03909-14. Epub 2014 Nov 3.

6.

Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.

DeAnda F, Hightower KE, Nolte RT, Hattori K, Yoshinaga T, Kawasuji T, Underwood MR.

PLoS One. 2013 Oct 16;8(10):e77448. doi: 10.1371/journal.pone.0077448. eCollection 2013.

7.

Emergency department treatments and physiotherapy for acute whiplash: a pragmatic, two-step, randomised controlled trial.

Lamb SE, Gates S, Williams MA, Williamson EM, Mt-Isa S, Withers EJ, Castelnuovo E, Smith J, Ashby D, Cooke MW, Petrou S, Underwood MR; Managing Injuries of the Neck Trial (MINT) Study Team.

Lancet. 2013 Feb 16;381(9866):546-56. doi: 10.1016/S0140-6736(12)61304-X. Epub 2012 Dec 19.

PMID:
23260167
8.

Strengthening and stretching for rheumatoid arthritis of the hand (SARAH): design of a randomised controlled trial of a hand and upper limb exercise intervention--ISRCTN89936343.

Sarah Trial Team, Adams J, Bridle C, Dosanjh S, Heine P, Lamb SE, Lord J, McConkey C, Nichols V, Toye F, Underwood MR, Williams MA, Williamson EM.

BMC Musculoskelet Disord. 2012 Nov 24;13:230. doi: 10.1186/1471-2474-13-230.

9.

The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults.

Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):297-301. doi: 10.1097/QAI.0b013e31826bfd02.

10.

Group cognitive behavioural interventions for low back pain in primary care: extended follow-up of the Back Skills Training Trial (ISRCTN54717854).

Lamb SE, Mistry D, Lall R, Hansen Z, Evans D, Withers EJ, Underwood MR; Back Skills Training Trial Group.

Pain. 2012 Feb;153(2):494-501. doi: 10.1016/j.pain.2011.11.016. Epub 2012 Jan 9.

PMID:
22226729
11.

Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.

Quashie PK, Mespl├Ęde T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA.

J Virol. 2012 Mar;86(5):2696-705. doi: 10.1128/JVI.06591-11. Epub 2011 Dec 28.

12.

Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.

Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL 3rd, Broderick T, Sigethy S, Seki T, Kobayashi M, Underwood MR.

Antimicrob Agents Chemother. 2011 Oct;55(10):4552-9. doi: 10.1128/AAC.00157-11. Epub 2011 Aug 1.

13.

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor.

Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T.

Antimicrob Agents Chemother. 2011 Feb;55(2):813-21. doi: 10.1128/AAC.01209-10. Epub 2010 Nov 29.

14.

Group cognitive behavioural treatment for low-back pain in primary care: a randomised controlled trial and cost-effectiveness analysis.

Lamb SE, Hansen Z, Lall R, Castelnuovo E, Withers EJ, Nichols V, Potter R, Underwood MR; Back Skills Training Trial investigators.

Lancet. 2010 Mar 13;375(9718):916-23. doi: 10.1016/S0140-6736(09)62164-4. Epub 2010 Feb 25.

PMID:
20189241
15.

Socioeconomic status predicts functional disability in patients participating in a back pain trial.

Moffett JA, Underwood MR, Gardiner ED.

Disabil Rehabil. 2009;31(10):783-90. doi: 10.1080/09638280802309327.

PMID:
19034721
16.

Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.

Underwood MR, Ross LL, Irlbeck DM, Gerondelis P, Rouse E, St Clair MH, Trinh L, Parkin N, Lanier E.

J Infect Dis. 2009 Jan 1;199(1):84-8. doi: 10.1086/595296.

PMID:
19032103
17.

Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics.

Nakahara K, Wakasa-Morimoto C, Kobayashi M, Miki S, Noshi T, Seki T, Kanamori-Koyama M, Kawauchi S, Suyama A, Fujishita T, Yoshinaga T, Garvey EP, Johns BA, Foster SA, Underwood MR, Sato A, Fujiwara T.

Antiviral Res. 2009 Feb;81(2):141-6. doi: 10.1016/j.antiviral.2008.10.007. Epub 2008 Nov 21.

PMID:
19027039
18.

The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.

Garvey EP, Johns BA, Gartland MJ, Foster SA, Miller WH, Ferris RG, Hazen RJ, Underwood MR, Boros EE, Thompson JB, Weatherhead JG, Koble CS, Allen SH, Schaller LT, Sherrill RG, Yoshinaga T, Kobayashi M, Wakasa-Morimoto C, Miki S, Nakahara K, Noshi T, Sato A, Fujiwara T.

Antimicrob Agents Chemother. 2008 Mar;52(3):901-8. Epub 2007 Dec 26. Erratum in: Antimicrob Agents Chemother. 2008 May;52(5):1899.

19.

Do baseline characteristics predict response to treatment for low back pain? Secondary analysis of the UK BEAM dataset [ISRCTN32683578].

Underwood MR, Morton V, Farrin A; UK BEAM Trial Team.

Rheumatology (Oxford). 2007 Aug;46(8):1297-302. Epub 2007 May 23.

PMID:
17522096
20.

Design considerations in a clinical trial of a cognitive behavioural intervention for the management of low back pain in primary care: Back Skills Training Trial.

Lamb SE, Lall R, Hansen Z, Withers EJ, Griffiths FE, Szczepura A, Barlow J, Underwood MR; Back Skills Training Trial (BeST) Team.

BMC Musculoskelet Disord. 2007 Feb 22;8:14.

21.

Managing Injuries of the Neck Trial (MINT): design of a randomised controlled trial of treatments for whiplash associated disorders.

Lamb SE, Gates S, Underwood MR, Cooke MW, Ashby D, Szczepura A, Williams MA, Williamson EM, Withers EJ, Mt Isa S, Gumber A; MINT Study Team.

BMC Musculoskelet Disord. 2007 Jan 26;8:7.

22.

Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility.

Ross LL, Parkin N, Gerondelis P, Chappey C, Underwood MR, St Clair MH, Lanier ER.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):567-70.

PMID:
17075395
23.

Asking older people about fear of falling did not have a negative effect.

Underwood MR, Parsons S, Eldridge SM, Spencer AE, Feder GS.

J Clin Epidemiol. 2006 Jun;59(6):629-34.

PMID:
16713526
24.

Patient perceptions of physical therapy within a trial for back pain treatments (UK BEAM) [ISRCTN32683578].

Underwood MR, Harding G, Klaber Moffett J; UK BEAM trial team.

Rheumatology (Oxford). 2006 Jun;45(6):751-6. Epub 2006 Jan 17.

PMID:
16418201
25.

Diagnosing and treating gout.

Katbamna R, Sutaria S, Underwood MR.

Practitioner. 2005 Nov;249(1676):773-7. Review. No abstract available.

PMID:
16296653
26.

Back pain and health policy research: the what, why, how, who, and when.

Wyatt M, Underwood MR, Scheel IB, Cassidy JD, Nagel P.

Spine (Phila Pa 1976). 2004 Oct 15;29(20):E468-75. Review.

PMID:
15480125
27.

Important determinants of self-efficacy in patients with chronic musculoskeletal pain.

Rahman A, Ambler G, Underwood MR, Shipley ME.

J Rheumatol. 2004 Jun;31(6):1187-92.

PMID:
15170934
28.

Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus.

Underwood MR, Ferris RG, Selleseth DW, Davis MG, Drach JC, Townsend LB, Biron KK, Boyd FL.

Antimicrob Agents Chemother. 2004 May;48(5):1647-51.

29.

Identification of peptides that inhibit the DNA binding, trans-activator, and DNA replication functions of the human papillomavirus type 11 E2 protein.

Deng SJ, Pearce KH, Dixon EP, Hartley KA, Stanley TB, Lobe DC, Garvey EP, Kost TA, Petty RL, Rocque WJ, Alexander KA, Underwood MR.

J Virol. 2004 Mar;78(5):2637-41.

30.

Homelessness: a problem for primary care?

Riley AJ, Harding G, Underwood MR, Carter YH.

Br J Gen Pract. 2003 Jun;53(491):473-9.

31.

Community management of knee pain in older people: is knee pain the new back pain?

Underwood MR.

Rheumatology (Oxford). 2004 Jan;43(1):2-3. Epub 2003 Aug 15. No abstract available.

PMID:
12923284
32.

In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses.

Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ, Drach JC, Townsend LB, Underwood MR, Biron KK, Kern ER.

Antimicrob Agents Chemother. 2003 Jul;47(7):2186-92.

33.

An evaluation of personal medical services: the times they are a changin'.

Riley AJ, Harding G, Meads G, Underwood MR, Carter YH.

J Interprof Care. 2003 May;17(2):127-39.

PMID:
12745295
34.

Understanding the process of care for musculoskeletal conditions--why a biomedical approach is inadequate.

Foster NE, Pincus T, Underwood MR, Vogel S, Breen A, Harding G.

Rheumatology (Oxford). 2003 Mar;42(3):401-4. No abstract available.

PMID:
12626788
35.

Disseminating and implementing the results of back pain research in primary care.

van Tulder MW, Croft PR, van Splunteren P, Miedema HS, Underwood MR, Hendriks HJ, Wyatt ME, Borkan JM.

Spine (Phila Pa 1976). 2002 Mar 1;27(5):E121-7.

PMID:
11880848
37.

Review of the role of progesterone in the management of postnatal mood disorders.

Granger AC, Underwood MR.

J Psychosom Obstet Gynaecol. 2001 Mar;22(1):49-55. Review.

PMID:
11317610
38.

Differences in DNA packaging genes and sensitivity to benzimidazole ribonucleosides between human cytomegalovirus strains AD169 and Towne.

Krosky PM, Ptak RG, Underwood MR, Biron KK, Townsend LB, Drach JC.

Antivir Chem Chemother. 2000 Sep;11(5):349-52.

PMID:
11142634
39.

Searching for antiviral drugs for human papillomaviruses.

Underwood MR, Shewchuk LM, Hassell AM, Phelps WC.

Antivir Ther. 2000 Dec;5(4):229-42. Review.

PMID:
11142617
40.

Management of deliberate self harm in general practice: a qualitative study.

Prasad LR, Gantley MM, Underwood MR.

Br J Gen Pract. 1999 Sep;49(446):721-4.

41.

Exercise and the prevention of back pain disability.

Underwood MR.

Br J Sports Med. 2000 Feb;34(1):5. Review. No abstract available.

42.

Evaluation of two time-specific back pain outcome measures.

Underwood MR, Barnett AG, Vickers MR.

Spine (Phila Pa 1976). 1999 Jun 1;24(11):1104-12.

PMID:
10361660
43.

Effect of UK national guidelines on services to treat patients with acute low back pain: follow up questionnaire survey.

Barnett AG, Underwood MR, Vickers MR.

BMJ. 1999 Apr 3;318(7188):919-20. No abstract available.

44.

Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56.

Krosky PM, Underwood MR, Turk SR, Feng KW, Jain RK, Ptak RG, Westerman AC, Biron KK, Townsend LB, Drach JC.

J Virol. 1998 Jun;72(6):4721-8.

45.

Randomised controlled trials in general practice: time for international collaboration.

Underwood MR, Carter YH.

Inj Prev. 1998 Mar;4(1):6-8. No abstract available.

46.
47.

Crisis: what crisis?

Underwood MR.

Eur Spine J. 1998;7(1):2-5. Review.

48.

The Cys607-->Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients.

Baldanti F, Underwood MR, Talarico CL, Simoncini L, Sarasini A, Biron KK, Gerna G.

Antimicrob Agents Chemother. 1998 Feb;42(2):444-6.

49.
50.

Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product.

Underwood MR, Harvey RJ, Stanat SC, Hemphill ML, Miller T, Drach JC, Townsend LB, Biron KK.

J Virol. 1998 Jan;72(1):717-25.

Supplemental Content

Loading ...
Support Center